Publications by authors named "Andy Rawstron"

Claim this Profile
C
COVID-19-related mortality in a real-world cohort of 18 883 patients with premalignant and malignant haematological neoplasms: An analysis from the UK's Haematological Malignancy Research Network.
Alexandra Smith, Clare Frobisher, Abraham Varghese, Andy Rawstron, Simon Crouch

Br J Haematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Doubling in median survival in patients diagnosed with multiple myeloma 2005-2019; a real-world study from the UK's Haematological Malignancy Research Network.
Alexandra Smith, Timothy Bagguley, Eve Roman, Simon Crouch, Russell Patmore, Andy Rawstron

Haematologica· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities.
Kostas Stamatopoulos, Sarka Pavlova, Othman Al-Sawaf, Thomas Chatzikonstantinou, Christina Karamanidou, Andy Rawstron

Hemasphere· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial.
Ruth M de Tute, Gordon Cook, David A Cairns, Julia M Brown, Jamie Cavenagh, Andy C Rawstron

Bone Marrow Transplant· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial.
Talha Munir, Jake Emmerson, Anna Hockaday, Jamie B Oughton, Dena Howard, Andy Rawstron

Br J Haematol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity.
James I Robinson, Md Yuzaiful Md Yusof, Vinny Davies, Dawn Wild, Michael Morgan, Andy C Rawstron

EBioMedicine· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
Ruth M de Tute, Charlotte Pawlyn, David A Cairns, Faith E Davies, Tom Menzies, Andy Rawstron

J Clin Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis.
Jack Arnold, Edward M Vital, Shouvik Dass, Aamir Aslam, Andy C Rawstron

Front Immunol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study.
David Allsup, Dena Howard, Jake Emmerson, Anna Hockaday, Andy Rawstron

Br J Haematol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL.
Marwan Kwok, Ceri Oldreive, Andy C Rawstron, Anshita Goel, Grigorios Papatzikas

Blood· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.
Md Yuzaiful Md Yusof, Edward M Vital, Damien M McElvenny, Elizabeth M A Hensor, Sudipto Das, Andy C Rawstron

Arthritis Rheumatol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.
Peter Hillmen, Andy C Rawstron, Kristian Brock, Samuel Muñoz-Vicente, Francesca J Yates

J Clin Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.
Oliver C Cohen, Nicholas Counsell, Neil Rabin, Rakesh Popat, Roger G Owen, Andy Rawstron

Br J Haematol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells.
Katie B Holmes, Ildar I Sadreev, Andy C Rawstron, Tal Munir, David R Westhead

Oncogenesis· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly selective SYK inhibitor, GSK143, abrogates survival signals in chronic lymphocytic leukaemia.
Abraham M Varghese, Andy Rawstron, Darren Newton, Reuben M Tooze, Talha Munir

Br J Haematol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments.
Paolo Ghia, Andy Rawstron

Leukemia· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project.
Andy C Rawstron, Karl-Anton Kreuzer, Asha Soosapilla, Martin Spacek, Olga Stehlikova

Cytometry B Clin Cytom· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus.
Md Yuzaiful Md Yusof, Daniel Shaw, Yasser M El-Sherbiny, Emma Dunn, Andy C Rawstron

Ann Rheum Dis· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial.
Laura Collett, Dena R Howard, Talha Munir, Lucy McParland, Jamie B Oughton, Andy C Rawstron

Trials· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monoclonal B-cell lymphocytosis in a hospital-based UK population and a rural Ugandan population: a cross-sectional study.
Andy C Rawstron, Aloysius Ssemaganda, Ruth de Tute, Chi Doughty, Darren Newton

Lancet Haematol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial.
Jamie B Oughton, Laura Collett, Dena R Howard, Anna Hockaday, Talha Munir, Andy C Rawstron

Trials· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Emergence of CD19-Negative Human Antibody-Secreting Cells at the Plasmablast to Plasma Cell Transition.
Gururaj Arumugakani, Sophie J Stephenson, Darren J Newton, Andy Rawstron, Paul Emery

J Immunol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
Dena R Howard, Talha Munir, Lucy McParland, Andy C Rawstron, Anna Chalmers

Health Technol Assess· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation.
Abraham M Varghese, Dena R Howard, Christopher Pocock, Andy C Rawstron, George Follows

Br J Haematol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal residual disease is an independent predictor for 10-year survival in CLL.
Marwan Kwok, Andy C Rawstron, Abraham Varghese, Paul A S Evans, Sheila J M O'Connor

Blood· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis